Cutaneous T cell lymphoma: update on treatment
- 22 August 2012
- journal article
- review article
- Published by Wiley in International Journal of Dermatology
- Vol. 51 (9), 1019-1036
- https://doi.org/10.1111/j.1365-4632.2011.05337.x
Abstract
Background Cutaneous T‐cell lymphoma (CTCL) is a myeloproliferative disease with pronounced epidermotropism. The major subtypes of CTCL are mycosis fungoides and Sézary syndrome. Survival is dependent on the histological subtype and clinical stage. Early CTCL has a normal life expectancy, therefore early disease recognition and stage adapted treatment might help to ensure a good prognosis. Methods This is a review of recent advances in CTCL treatment based on literature review. Results Skin targeted therapies are useful for patch and limited plaque disease with phototherapy as the cornerstone of such treatments. More advanced disease will benefit from systemic mono‐ or combined treatments including drug therapy, extracorporeal photopheresis, and radiotherapy. In practice combined treatments may reduce adverse events and improve response rates. For selected younger patients, stem cell transplantation seems a third‐line option. Conclusions The therapeutic spectrum for CTCL has been advanced during the last years, providing the opportunity of tailored treatment for patients.Keywords
This publication has 108 references indexed in Scilit:
- The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL‐10 expression in cutaneous T‐cell lymphoma cellsBritish Journal of Pharmacology, 2011
- Photodynamic Therapy with the Silicon Phthalocyanine Pc 4 Induces Apoptosis in Mycosis Fungoides and Sezary SyndromeAdvances in Hematology, 2010
- Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapyBlood, 2010
- Innovative Therapy of Cutaneous T-Cell Lymphoma: Beyond Psoralen and Ultraviolet Light and Nitrogen MustardDermatologic Clinics, 2010
- Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-γ) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell LymphomasMolecular Therapy, 2010
- HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapyProceedings of the National Academy of Sciences of the United States of America, 2010
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2009
- Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 casesBlood, 2009
- Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Blood, 2007
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006